You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Transforming Growth Factor- ß in Cancer Therapy, Vols. 1 and 2, provides a compendium of findings about the role of transforming growth factor- ß (TGF- ß) in cancer treatment and therapy. The second volume, Cancer Treatment in Therapy, is divided into three parts. The companion volume details the role of TGF- ß on basic and clinical biology.
Transforming Growth Factor- ß in Cancer Therapy, Vols. 1 and 2, provides a compendium of findings about the role of transforming growth factor- ß (TGF- ß) in cancer treatment and therapy. The first volume, Basic and Clinical Biology, is divided into three parts. This volume’s companion, Cancer Treatment in Therapy, examines transforming growth factor- ß in other developing and advanced cancers and methods of treatment and therapy.
The fact that tumors are composed of both tumor cells and host cells has long been known. These tumor-associated cells include vascular endothelial cells and pe- cytes, as well as inflammatory cells such as neutrophils, monocytes, macrophages, mast cells and eosinophils, and lymphocytes. The tumor cells also interact with stromal cells and with elements of the tissue extracellular matrix. What has been less appreciated is the role that these cells could have in modulating the growth, invasion, and metastasis of the tumor. Early on, the elements of what we now call the tumor microenvironment were considered to be more or less innocent bysta- ers to the role of the tumor cells as they grew and...
Presents the broad outline of NIH organizational structure, theprofessional staff, and their scientific and technical publications covering work done at NIH.
None
TGF-beta, originally identified as a transforming growth factor with similar properties, is now known to exist as a family of factors with similar properties. These factors promote cell proliferation in some tissue types or conditions and induce cell differentiation in others. Features the latest information on the TGF-beta family and its receptors. Describes correlations between TGF-beta and certain cancers, including glioblastomas. Also contains reports of preliminary investigations of clinical applications for TGF-beta in many diseases, including leukemia and its use to accelerate wound healing.
Functional evidence obtained from somatic cell fusion studies indicated that a group of genes from normal cells might replace or correct a defective function of cancer cells. Tumorigenesis that could be initiated by two mutations was established by the analysis of hereditary retinoblastoma, which led to the eventual cloning of RB1 gene. The two-hit hypothesis helped isolate many tumor suppressor genes (TSG) since then. More recently, the roles of haploinsufficiency, epigenetic control, and gene dosage effects in some TSGs, such as P53, P16 and PTEN, have been studied extensively. It is now widely recognized that deregulation of growth control is one of the major hallmarks of cancer biological capabilities, and TSGs play critical roles in many cellular activities through signaling transduction networks. This book is an excellent review of current understanding of TSGs, and indicates that the accumulated TSG knowledge has opened a new frontier for cancer therapies.
The Twelfth Annual Washington Spring Symposium on Health Sciences attracted over 300 scientists from 20 countries. It was held at the Lisner Auditorium of the George Washington University in Washington, D.C. during June 1-5, 1992. The theme of the meeting was "Growth Factors, Peptides, and Receptors," and speakers emphasized both basic and clinical research in these areas. The seven plenary sessions emphasized Peptides, Growth Factors, Peptide Receptors, Growth Factor Receptors, Second Messengers, Proliferation, and Clinical Correlations. The chapters in this volume are derived from each of these scientific sessions plus the poster and special sessions. The Abraham White Distinguished Scient...